These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30428832)

  • 1. Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions.
    Boublay N; Fédérico D; Pesce A; Verny M; Blanc F; Paccalin M; Desmidt T; Grosmaître P; Moreaud O; Relland S; Bravant E; Bouet R; Krolak-Salmon P
    BMC Geriatr; 2018 Nov; 18(1):280. PubMed ID: 30428832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early diagnosis of Lewy body disease in elderly individuals with subjective cognitive decline.
    Fujishiro H
    J Neurol Sci; 2019 Jun; 401():128-129. PubMed ID: 31078897
    [No Abstract]   [Full Text] [Related]  

  • 4. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
    Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
    J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and multimodal biomarker correlates of ADNI neuropathological findings.
    Toledo JB; Cairns NJ; Da X; Chen K; Carter D; Fleisher A; Householder E; Ayutyanont N; Roontiva A; Bauer RJ; Eisen P; Shaw LM; Davatzikos C; Weiner MW; Reiman EM; Morris JC; Trojanowski JQ;
    Acta Neuropathol Commun; 2013 Oct; 1():65. PubMed ID: 24252435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction.
    Kang SW; Jeon S; Yoo HS; Chung SJ; Lee PH; Sohn YH; Yun M; Evans AC; Ye BS
    Neurology; 2019 Apr; 92(17):e2015-e2026. PubMed ID: 30944239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cingulate Island Sign in Single Photon Emission Computed Tomography: Clinical Biomarker Correlations in Lewy Body Disease and Alzheimer's Disease.
    Futamura A; Hieda S; Mori Y; Sugimoto A; Kasai H; Kuroda T; Yano S; Kasuga K; Murakami H; Ikeuchi T; Ono K
    J Alzheimers Dis; 2021; 79(3):1003-1008. PubMed ID: 33361600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating 2-[
    Gjerum L; Frederiksen KS; Henriksen OM; Law I; Bruun M; Simonsen AH; Mecocci P; Baroni M; Dottorini ME; Koikkalainen J; Lötjönen J; Hasselbalch SG
    Neuroimage Clin; 2020; 27():102267. PubMed ID: 32417727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease.
    Reed BR; Mungas DM; Kramer JH; Ellis W; Vinters HV; Zarow C; Jagust WJ; Chui HC
    Brain; 2007 Mar; 130(Pt 3):731-9. PubMed ID: 17267522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.